Picard Medical, parent company of SynCardia Systems, has released its pre-recorded annual stockholder presentation in advance of the 2026 Annual Meeting scheduled for July 17. The presentation highlights an 85% year-over-year revenue increase for the first three months of 2026, driven by a 116% rise in U.S. revenue, with gross margin improving to 24% from negative 4% in 2025. It also provides updates on the next-generation Emperor platform, which aims to eliminate the external pneumatic driver, with an initial configuration retaining an external controller and battery and a longer-term goal of a fully implantable system; the company plans to pursue FDA Breakthrough Device designation, continue preclinical studies, submit an Investigational Device Exemption in 2028, and begin clinical study activities in 2029. Stockholders will vote on proposals including the election of directors, amendments to the capital structure, ratification of the independent auditor, and advisory votes on executive compensation.
Picard Medical, Inc.85% YoY revenue increase, gross margin improvement from -4% to 24%
Parent company's revenue growth and margin improvement reflect positively on SynCardia as its subsidiary